Mesoblast (ASX:MSB) told the market on 17 August 2026 that it had finished treating every patient in MSB-DR004, its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain caused by degenerative disc disease. The announcement starts a clock that ends in mid-calendar 2027, when the last treated patient completes 12 months of follow-up and top-line data becomes available.

The stock price was in the spotlight after its share price recorded a significant jump. The completion of dosing is a delivery milestone, not a result — nothing in the release says anything about whether rexlemestrocel-L works in back pain, and the read-out remains roughly ten months away.

What happened?

Mesoblast confirmed that 350 patients have now been randomised and treated in MSB-DR004, above the 300-patient target the company had set and reported as achieved on 14 July 2026, which it attributed to stronger-than-expected investigator demand.

The trial tests a single intra-discal injection of rexlemestrocel-L against a sham injection, with the primary endpoint being durable pain reduction at 12 months. Chief executive Dr Silviu Itescu described the completion of treatment as a momentous milestone as the company counts down to the 12-month read-out for what it hopes will be its first blockbuster product.

The story behind the numbers

Ryoncil, the company's first FDA-approved mesenchymal stromal cell therapy, generated net Revenue of US$36 million in the June 2026 quarter and US$115 million for the full year. Cash stood at US$102.9 million at 30 June 2026, with net operating cash outflow narrowing to US$9.3 million for the quarter.

Mesoblast drew US$50 million in June 2026 under a five-year Facility to retire an existing Loan facility, secured solely by a Royalty stream and carrying no early prepayment or exit fees.

Why this matters

Chronic low back pain associated with degenerative disc disease is a large, poorly served market. The strategic logic is that Ryoncil funds the Business at modest burn while the higher-value back pain asset works its way to a read-out. If MSB-DR004 succeeds, Mesoblast would own a non-opioid, single-administration option in a field where surgical and pharmacological alternatives are unsatisfying.

What is driving the Investment case?

Three threads run in parallel: Ryoncil's commercial launch and continued uptake momentum; a broader regulatory pipeline including a filed application for rexlemestrocel-L in a separate heart failure-related indication and an FDA-cleared registration trial pathway in Duchenne muscular dystrophy; and improved funding through the refinanced, royalty-secured facility.

The bull case

Mesoblast is one of very few ASX-listed biotechs with an approved product, recurring US revenue and a pivotal read-out inside twelve months. Ryoncil revenue exceeded the company's own initial projections in its first full year, and other programs extend that platform without a new Manufacturing build.

The bear case

The central risk is binary. A single Phase 3 trial in a pain indication with a sham control arm is a demanding test, and placebo response in back pain studies is notoriously high. Cash against continuing operating outflows leaves limited room for surprises if Ryoncil growth stalls.

What could move the share price next?

The MSB-DR004 top-line result expected in mid-calendar 2027 is the defining catalyst. Progress on the regulatory review for the heart failure-related indication, quarterly Ryoncil revenue disclosures and Mesoblast's FY26 full-year accounts are the nearer-term items.

Outlook

Mesoblast has moved from a company defined by trial execution risk to one with a revenue base beneath a high-stakes read-out. The next twelve months are mostly about proving that Ryoncil's growth is durable and that cash burn keeps narrowing.